We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel AI Blood Test Determines Response to Cancer Therapy

By LabMedica International staff writers
Posted on 23 May 2025

Expanding treatment options for pancreatic cancer patients is vital as more experimental therapies become available for the condition. More...

However, swift action is essential, as many pancreatic cancer cases are diagnosed at advanced stages, where the disease can progress rapidly. Clinicians currently rely on imaging tools to monitor the response to treatments and tumor progression, but these tools often provide results that are delayed and less reliable, especially for patients receiving immunotherapies. Immunotherapy can complicate the interpretation of these results. To address these challenges, an artificial intelligence (AI) method that detects DNA fragments shed by tumors into a patient’s blood could help clinicians assess treatment effectiveness more quickly and accurately.

Researchers at Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) tested a technique called ARTEMIS-DELFI (tumor-independent genome-wide cfDNA fragmentation profiles and repeat landscapes) using blood samples from participants in two major clinical trials of pancreatic cancer treatments. The results showed that ARTEMIS-DELFI could identify therapeutic responses more efficiently. Alongside ARTEMIS-DELFI, another method called WGMAF (tumor-informed plasma whole-genome sequencing) was also tested to analyze mutations. The study found that both ARTEMIS-DELFI and WGMAF were better predictors of treatment outcomes compared to imaging or other clinical and molecular markers two months after the start of treatment. However, ARTEMIS-DELFI was considered the superior method due to its simplicity and broader applicability.

In their study published in Science Advances, the researchers evaluated these two approaches for monitoring treatment response in patients participating in the phase 2 CheckPAC trial, which focused on immunotherapy for pancreatic cancer. The first method, WGMAF, analyzed DNA from tumor biopsies alongside cell-free DNA in blood samples to detect treatment responses. The second method, ARTEMIS-DELFI, employed machine learning to analyze millions of cell-free DNA fragments from just the patient’s blood samples. Both methods successfully identified which patients were responding to the treatments. However, not all patients had tumor samples, and when they did, many samples contained only a small proportion of cancer cells, mixed with normal pancreatic and other tissues, which made the WGMAF results harder to interpret.

ARTEMIS-DELFI, on the other hand, was simpler, worked with a larger group of patients, and produced more reliable results. The researchers then validated ARTEMIS-DELFI as an effective tool for monitoring treatment response in the second clinical trial, the PACTO trial. The results confirmed that ARTEMIS-DELFI could identify which patients were responding to treatment just four weeks after therapy began. The next step for the research team will be conducting prospective studies to test whether ARTEMIS-DELFI can help clinicians identify effective therapies more efficiently and improve patient outcomes. Additionally, a similar approach may be applied to monitor other cancers. Earlier this year, the team conducted a study showing that a variation of this cell-free fragmentation monitoring method, DELFI-TF, was also useful in evaluating the response to colon cancer therapy.

“The ‘fast-fail’ ARTEMIS-DELFI approach may be particularly useful in pancreatic cancer where changing therapies quickly could be helpful in patients who do not respond to the initial therapy,” said lead study author Carolyn Hruban. “It’s simpler, likely less expensive, and more broadly applicable than using tumor samples.”

Related Links:
Johns Hopkins Kimmel Cancer Center


New
Gold Member
Hematology Analyzer
Medonic M32B
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.